Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) announced its participation in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 10:00am EST. The event will be available via live webcast on the Company’s website, with an archive accessible for 30 days post-event. Provention Bio focuses on developing therapies for immune-mediated diseases, targeting conditions like type 1 diabetes and lupus. More information can be found on their website.

RED BANK, N.J., Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16^th, 2022 at 10:00am EST.

The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation. 

About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:
Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contacts:
Robert Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235

Sam Martin, Argot Partners
proventionbio@argotpartners.com   
212-600-1902

Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-virtual-svb-leerink-11th-annual-global-healthcare-conference-301479345.html

SOURCE Provention Bio, Inc.

FAQ

What date will Provention Bio present at the SVB Leerink Conference?

Provention Bio will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022.

What time is Provention Bio's presentation at the conference?

The presentation is scheduled for 10:00am EST.

How can I access Provention Bio's presentation?

The presentation can be accessed via live webcast on Provention Bio's website.

What is the focus of Provention Bio, Inc.?

Provention Bio is focused on developing therapies to intercept and prevent immune-mediated diseases.

What diseases does Provention Bio target?

Provention Bio targets autoimmune diseases, including type 1 diabetes, celiac disease, and lupus.

How long will the webcast of the presentation be available?

The webcast will be archived on the Company’s website for 30 days following the presentation.